Semaglutide vs Tirzepatide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It is FDA-approved under the brand names Ozempic (diabetes) and Wegovy (weight loss) and has become one of the most widely discussed peptides in mainstream health conversations.
Full profileTirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), it produces greater weight loss than any approved GLP-1 monotherapy in clinical trials.
Full profile| Semaglutide | Tirzepatide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Ozempic, Wegovy, Rybelsus, GLP-1 agonist | LY3298176, Mounjaro, Zepbound |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 0.25mg–2.4mg mg, once weekly (injectable); once daily (oral Rybelsus) | 2.5mg–15mg mg, Once weekly subcutaneous injection |
| Administration | Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus) | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Key side effects | Nausea (very common, especially during dose escalation), Vomiting, Diarrhea or constipation, Reduced appetite (intended effect) | Nausea (most common, especially during titration), Vomiting, Diarrhea, Constipation |
| Cited sources | 4 references | 4 references |
Key differences
- Administration: Semaglutide — Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus); Tirzepatide — Subcutaneous injection (abdomen, thigh, or upper arm).
- Frequency: Semaglutide is typically once weekly (injectable); once daily (oral Rybelsus); Tirzepatide is Once weekly subcutaneous injection.
How each works
Semaglutide
Semaglutide has robust clinical trial data — including the STEP and SUSTAIN trial series — demonstrating significant weight loss (15–20% body weight), glycemic control, and cardiovascular risk reduction. It works by mimicking the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, and reducing appetite via central nervous system signaling.
Tirzepatide
The SURMOUNT-1 trial (N=2539) demonstrated up to 22.5% mean body weight reduction over 72 weeks at the 15mg dose — the highest efficacy ever recorded for a pharmaceutical weight loss agent at time of publication. The dual mechanism leverages GIP's potentiation of insulin secretion and adipose tissue effects alongside GLP-1's appetite suppression and gastric motility slowing. Head-to-head data (SURMOUNT-5) shows tirzepatide outperforms semaglutide 2.4mg for weight loss.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.